Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

12.03
-0.0600-0.50%
Post-market: 12.040.0100+0.08%18:00 EDT
Volume:863.19K
Turnover:10.39M
Market Cap:1.92B
PE:270.97
High:12.33
Open:11.85
Low:11.64
Close:12.09
52wk High:42.44
52wk Low:11.25
Shares:159.53M
Float Shares:70.11M
Volume Ratio:0.53
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0444
EPS(LYR):0.0444
ROE:3.29%
ROA:0.24%
PB:7.41
PE(LYR):270.97

Loading ...

Vertex Stock Jumps. What Wall Street Is Saying About Its Kidney Drug Trial. -- Barrons.com

Dow Jones
·
Mar 10

Vertex Pharmaceuticals: Upgraded Confidence in Povetacicept Drives Strengthened Buy Thesis After Robust Phase III RAINIER Data in IgA Nephropathy

TIPRANKS
·
Mar 10

Vertex Raises FY Dividend Plan to Y35.00

Dow Jones
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and HCA Healthcare (HCA)

TIPRANKS
·
Mar 10

Major Vertex Stakeholder Makes Notable Move With Fresh Stock Sale

TIPRANKS
·
Mar 10

Vertex Pharmaceuticals up 7% at $492 after positive Povetacicept results

TIPRANKS
·
Mar 10

Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why

Benzinga_recent_news
·
Mar 10

Vertex Pharmaceuticals announces positive week 36 results in Povetacicept study

TIPRANKS
·
Mar 10

BMO Capital Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Mar 06

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Mar 06

Vertex says JOURNAVX demonstrates ‘effective’ pain management in study

TIPRANKS
·
Mar 05

Is Vertex Pharmaceuticals (VRTX) Still Attractively Priced After Its Multi Year Share Price Run?

Simply Wall St.
·
Mar 05

Press Release: Vertex Innovations Names Jason Hughes VP of Mission Critical Operations

Dow Jones
·
Mar 04

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Mar 03

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $600 From $530, Maintains Outperform Rating

MT Newswires Live
·
Mar 02

CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus

Simply Wall St.
·
Mar 01

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 28

Vertex Broadens Growth Story With Gene Editing And Non Opioid Pain Therapies

Simply Wall St.
·
Feb 28

Vertex CEO Chris Young and CFO John Schwab to Join Fireside Chats at Citizens JMP Technology Conference and Morgan Stanley TMT Conference

Reuters
·
Feb 27

Daiwa Securities Adjusts Vertex Pharmaceuticals PT to $561 From $500, Maintains Buy Rating

MT Newswires Live
·
Feb 26